Professional
Added to YB: 2024-11-08
Pitch date: 2024-11-06
GKOS [neutral]
Glaukos Corporation
-22.85%
current return
Author Info
Pernas Research is a former CIO of a $3.5B fund that now share actionable stock research. Sign up for the newsletter.
Company Info
Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, develops therapies for the treatment of glaucoma, corneal disorders, and retinal diseases in the United States and internationally.
Market Cap
$5.2B
Pitch Price
$141.12
Price Target
N/A
Dividend
N/A
EV/EBITDA
-102.02
P/E
-58.28
EV/Sales
10.65
Sector
Health Care Equipment and Supplies
Category
value
Pernas Research Passes On: Glaukos Corporation
GKOS pass: Leader in MIGS w/ strong patent portfolio. Revenue growth driven by iStent, but $150M annual burn. 65% stock run-up YTD. Concerns: MIGS market growth, reimbursement challenges, modest efficacy, limited standalone use. P/S 19x too rich despite aging population play.
Read full article (1 min)